Samsung Biologics Co., Ltd.
About Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd. Industry Content
Categories
-
KR -
2018On CPHI since
-
1000 - 4999Employees
Company types
Contact info
-
-
-
300 Songdo Bio Way (daero), Yeonsu-gu, 21987, Incheon, Korea, Republic of
Meet us at
CPHI Frankfurt 2022
Messe Frankfurt, Frankfurt, Germany
1-3 November 2022
Products from Samsung Biologics Co., Ltd. (3)
-
Product New plant, Plant 4
To fulfill the increasing demand of life-saving solutions for patients' lives all over the world, we decided to drive forward with building our new facility, Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your glo... -
Product S-Cellerate™ to BLA
As biologics in development get closer to commercialization, drug developers are expected to implement rigorous process control measures to avoid potential manufacturing inconsistencies. A thorough understanding of process parameters and their potential impact on the product quality attributes and safety prof... -
Product S-Cellerate™ to IND
Speed to market is becoming increasingly crucial for commercial success. Enhanced timelines, which quickly advance the platform product to proof-of-concept (PoC) and first-in-human (FiH) studies, are already the new norm. Samsung Biologics’ S-Cellerate™ represents the faster path to IND, achieved through care...
Samsung Biologics Co., Ltd. Resources (19)
-
News Samsung Biologics and AstraZeneca expand manufacturing partnership to include COVID-19 and cancer therapies
CDMO currently manufacturing LAAB combination treatment and will start on cancer immunotherapy product from next year -
Sponsored Content Learning Lab: How COVID-19 is Redefining Drug Development and Manufacturing
Watch this Learning Lab video presented by Chris McPherson, Principal Scientist, DS Manufacturing, Samsung Biologics, which details how CDMOs have reacted to the challenging ‘Black Swan’ event that is the COVID-19 pandemic by initiating ‘Green Swan’ thinking that is optimising timelines via agile execution, transparent communication and teamwork, and innovative regulatory strategy and support. -
Brochure Plant 4 Brochure
Learn more about Samsung Biologics' Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your global presence. -
News Samsung Biologics and Kineta strike cancer immunotherapy development and manufacturing deal
Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours -
Brochure S-CellerateTM to IND
The S-CellerateTM platform utilizes Samsung Biologics' breadth of knowledge gained through the Design of Experiments-based methodology to obtain optimal productivity in cell culture, the highest yield and quality in downstream processes, and the right safety and stability profile in formulation development -
News Samsung Biologics to provide 'streamlining' services for KAHR Medical's cancer immunotherapy candidate
The CDMO will also provide IND filling support for KAHR's drug candidate DSP502 -
Brochure S-CellerateTM to BLA
Learn more about Samsung Biologics' S-CellerateTM to BLA platform which offers the full spectrum of process validation services including well-designed process characterization (PC) and accelerated process performance qualification (PPQ). -
News Samsung Biologics expands portfolio with mRNA vaccine manufacturing capability
The additional manufacturing suite at the CDMO's Songdo site is anticipated to be ready for cGMP operations within the first half of 2022 -
Whitepaper Mitigating Risks Associated with Single-Use Systems
There is no simple, clear-cut answer when determining which system is the better of the two.However, it is crucial to understand both the benefits and risks associated with each system andwhich will better suit your specific needs or circumstances when planning a major equipment purchaseor selecting a CDMO. As your forward-thinking CDMO partner, Samsung Biologics offers bothtechnologies as part of our contract manufacturing engagement and has the skill, knowledge, andresources required to determine which technology is best for your product, as well as how you canmitigate long-term project risks as effectively as possible. -
News Samsung Biologics to provide fill-finish manufacturing for Moderna COVID vaccine
The CDMO will support the production of hundreds of millions of doses from its facility in Incheon, South Korea. -
Whitepaper Monoclonal Antibody Manufacturing for Biopharma - Should I build or outsource
A company’s strategy is crucial for determining future success, and therefore, it needs to constantly change in line with market dynamics. Although building in-house offer the advantage of direct control, the time, labor, and spend required to implement this often makes it the inefficient choice. From this whitepaper, you will learn about the parameters to consider when selecting a CDMO. -
News COVID-19 has exacerbated contract manufacturing challenges but industry continues to respond well to crisis: experts
Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told -
Video Virtual Exhibition Hall
Do you want to know more about Samsung Biologics? Please visit our latest Virtual Exhibition Hall! -
.jpg)
News Samsung Biologics adds fourth plant due to growing demand
Plant 4 will add 256 KL capacity to its site, which is scheduled to commence manufacturing activities in the second half of 2022. -
![[Manifesto Film] Our Promise to Clients](https://www.cphi-online.com/Manifesto_thumbnail-file107718.JPG)
Video [Manifesto Film] Our Promise to Clients
Manufacture The Future
Imagine a future
Where ideas become cures
A future
where innovation and technology
help pioneer endless possibilities
to make a lasting impact
A future
Where efficiency meets expertise
Collaboration enables customizationDedication empowers breakthroughs
This is a place where we help your ingenuity
to build a better future
A future we all want to live in.
Samsung Biologics
-
.jpg)
News Samsung Biologics invests in expanding aseptic filling capacity at Incheon site
Through this expansion, the CDMO will increase the total lyophilization capacity by 246% of the current capacity. -
Video Navigating the CDMO Market: Hurdles, Transformation & Opportunities
This webinar originally aired as part of CPHI Discover - 17-28 May 2021
After a tumultuous year, what are the key factors shaping the future of the CDMO market? This session will bring together industry heavyweights for an outlook on 2021 and beyond.
Join this live stream session to gain insights into: CDMO market outlook, where do the most significant opportunities lie? What does technology and innovation look like in the post-COVID-19 CDMO market? Manufacturing vaccines at scale – what are the concerns of the CDMO side? Onshoring API Manufacturing – can we expect more manufacturers to expand operations on home turf? What are the key factors that will be shaping the future of the CDMO service market? This session will feature a live Q&A with the speakers.
-
News Samsung BioLogics’ End-to-End service to maximize client satisfaction
Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea. Samsung BioLogics provides an end-to-end service for contracted biopharmaceutical production from cell-line development, process development, and commercial manufacturing of both Drug Substance and Drug Product. The company has constructed three mega plants having a total bioreactor capacity of 362,000 liters. This makes Samsung BioLogics the world’s largest CDMO.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance